ABP Stock Overview
AB Science, a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AB Science S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.31 |
| 52 Week High | €7.05 |
| 52 Week Low | €3.31 |
| Beta | 0.99 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -60.35% |
| 33 Year Change | -68.10% |
| 5 Year Change | -14.42% |
| Change since IPO | -83.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABP | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 1.7% |
| 1Y | -60.3% | 20.9% | 13.1% |
Return vs Industry: ABP underperformed the UK Pharmaceuticals industry which returned -7.1% over the past year.
Return vs Market: ABP underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| ABP volatility | |
|---|---|
| ABP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ABP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ABP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 89 | Alain Moussy | www.ab-science.com |
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications.
AB Science S.A. Fundamentals Summary
| ABP fundamental statistics | |
|---|---|
| Market cap | €140.97m |
| Earnings (TTM) | -€16.88m |
| Revenue (TTM) | €777.00k |
181.4x
P/S Ratio-8.3x
P/E RatioIs ABP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABP income statement (TTM) | |
|---|---|
| Revenue | €777.00k |
| Cost of Revenue | €92.00k |
| Gross Profit | €685.00k |
| Other Expenses | €17.57m |
| Earnings | -€16.88m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 88.16% |
| Net Profit Margin | -2,173.10% |
| Debt/Equity Ratio | -97.2% |
How did ABP perform over the long term?
See historical performance and comparison